On January 1, in the children's ICU ward of Zaozhuang Maternal and Child Health Hospital, medical staff cheered for a 4-year-old child with spinal muscular atrophy who completed the targeted treatment drug Nocinasone sodium.
At about 7:00 a.m. on January 1, 2022, a 4-year-old child with spinal muscular atrophy in Zaozhuang City, Shandong Province, successfully injected the targeted therapeutic drug Nocinazone sodium. It is reported that Nocinassin sodium injection is China's first imported drug approved for the treatment of spinal muscular atrophy, and when it entered the Chinese market in 2019, the price per injection was nearly 700,000 yuan. In the 2021 national medical insurance catalogue drug negotiations, Northinalsan sodium injection was "soul bargaining" and entered the new version of the medical insurance drug catalogue at a price of 33,000 yuan per needle.
Xinhua News Agency reporter Guo Xulei photo report
On January 1, in the children's ICU ward of Zaozhuang Maternal and Child Health Hospital, medical staff prepared to inject the targeted therapy drug Nocinazone sodium for a 4-year-old child with spinal muscular atrophy.
On January 1, in the children's ICU ward of Zaozhuang Maternal and Child Health Hospital, medical staff injected a 4-year-old child with spinal muscular atrophy with a targeted treatment drug, nocinazone sodium.
Editors: Zhang Weige, Song Weiwei, Zhao Tingting, Zhang Manyi